anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Huntington's disease (HD) is a genetic neurodegenerative disorder caused by an abnormal expansion of a trinucleotide CAG repeat region of the huntingtin gene (HTT). The majority of patients with HD do not present with symptoms until the age of 40-50 years old, on average, which is referred to as Adult-onset HD (AoHD). A much smaller percentage of patients with HD receive a motor diagnosis prior to the age of 21, which is referred to as Juvenile-onset HD (JoHD). Although patients with JoHD have the same core triad of cognitive, behavior, and motor symptoms, there are unique clinical characteristics that are distinct from AoHD. Specifically, patients with JoHD have less chorea compared to patients with AoHD, often presenting with rigidity and bradykinesia. However, due to the rarity, there is a lack of data regarding symptom characterization, neurobiology and progression of JoHD. Large-scale observational studies have been performed in AoHD, which have broadened our understanding of HD and opened the doors for the development and conduct of clinical trials. Patients with JoHD have been excluded from clinical trials, leaving patients and their families feeling hopeless and abandoned by the scientific community. Large-scale, longitudinal studies in patients with JoHD are critical to bettering our understanding of this devastating disease and providing hope to patients who have felt left behind as therapeutic strategies advance in AoHD.

In an effort to better understand the developmental aspects of this brain disease, the current study proposes to evaluate brain structure and function in children, adolescents, and young adults (ages 6-30) who have been diagnosed with JoHD. Brain structure will be evaluating using Magnetic Resonance Imaging (MRI) with quantitative measures of the entire brain, cerebral cortex, as well as white matter integrity via Diffusion Tensor Imaging. Brain function will be assessed by cognitive tests, behavioral assessment, and physical and neurologic evaluation. This study will test the hypothesis that comprehensive and longitudinal assessments of brain function and brain structure may produce reliable biomarkers of disease progression in JoHD.
The present disclosure may provide a user terminal for quality control. The user terminal may be communicatively connected to a medical imaging server. The user terminal may receive, from the medical imaging server, a quality control result regarding one or more medical images of an examiner newly captured by a medical imaging device. The quality control result may at least include a quality level of the one or more medical images. The user terminal may also display a message prompt interface for displaying the quality control result. The message prompt interface may at least include a visual element whose configuration is determined based on the quality level of the one or more medical images.
Patients in the control arm will receive a usual care dressing using absorbent cotton pads placed in contact with the wound. Dressings will be applied directly to the wound surface to protect the wound surface environment and the wound bed. Dressing chances are scheduled every 48h.
BACKGROUND: Accumulating evidence has linked dyslipidemia during pregnancy to the risk of delivering infants born either large for gestational age (LGA) or small for gestational age (SGA). However, the effects of the vitamin D status on these relationships require further investigation. This study investigated whether the relationship between lipid profiles and the risk of LGA or SGA was influenced by vitamin D levels during the second trimester.
METHODS: Maternal lipid profile levels, including total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and vitamin D levels, were measured in a cohort of 6,499 pregnant women during the second trimester. Multivariate regression models and subgroup analyses were employed to evaluate the potential associations between maternal lipid profiles, vitamin D levels, and the risk of LGA or SGA.
RESULTS: The prevalence of SGA infants was 9.8% (n=635), whereas that of LGA infants was 6.9% (n=447). Maternal TG levels were found to be positively associated with the risk of LGA (odds ratio [OR] = 1.41, 95% confidence interval [CI]:1.17-1.70), whereas a negative association was observed between maternal TG, TC, LDL-C levels, and risk of SGA. Additionally, mothers with higher HDL-C levels were less likely to give birth to an LGA infant (OR=0.58, 95% CI:0.39-0.85). Importantly, associations between TG, TC, LDL-c, and SGA as well as between TG and LGA were primarily observed among pregnant women with insufficient vitamin D levels. As for HDL-C, the risk of LGA was lower in mothers with sufficient vitamin D (OR = 0.42, 95% CI:0.18-0.98) compared to those with insufficient vitamin D (OR = 0.65, 95% CI:0.42-0.99).
CONCLUSION: Vitamin D status during the second trimester exerts a modifying effect on the association between lipid profiles and the risk of LGA and SGA infants.
Minocycline, which is a second-generation tetracycline, has been found to inhibit Nitric Oxide Synthase (NOS) and inflammatory cytokines. These are some of the primary mechanisms that have been proposed to explain its neuroprotective and neuroplastic effects in several animal and human models of neurological and psychiatric diseases, including Parkinson's disease and schizophrenia. There are only three clinical trials with minocycline in schizophrenia subjects. A more definitive clinical trial in a larger sample with optimized and cost-effective design using a comprehensive cognitive battery and a global assessment of schizophrenia symptom domains is necessary to examine the efficacy of minocycline. If minocycline improves psychopathology and potentially other symptoms (including cognitive function) for schizophrenia, the treatment could be easily implemented in the existing treatment delivery system at relatively low cost and have the potential for making a significant public health impact. The investigators plan to recruit 120 individuals with early course schizophrenia who are currently on second-generation antipsychotic (SGA) medications and are experiencing persistent symptoms in at least the moderate range. In an effort to limit placebo response, which is notoriously high in psychiatric population, the investigators are using an adaptive design. Since, there is growing evidence to support the inflammatory hypothesis of schizophrenia, the investigators will also explore whether cytokine levels mediate the response from minocycline treatment.
According to the thyroid function, if the initial free thyroxine(FT4) ≥ 3 times the normal value, the initial dose of methimazole is 30mg/ day, the thyroid function will be tested every four weeks, and the dose will be reduced when thyroid stimulating hormone(TSH) \> normal lower limit or free triiodothyronine(FT3) \< normal lower limit or FT4 \< normal lower limit. The dose will be reduced according to the clinical routine, specifically, every day (30 mg→20 mg→10 mg→5mg→2.5 mg) If the initial FT4 is less than 3 times the normal value, the initial dose of methimazole is 15mg/ day, and the thyroid function is tested every four weeks. When TSH is greater than the normal lower limit or FT3 is less than the normal lower limit or FT4 is less than the normal lower limit, the dose will be reduced according to the clinical routine, specifically every day for 24 months. If TSH \> 100 mIU/L occurs during the treatment, the reduction speed will be accelerated, and 1-2 dose levels can be skipped.
FIELD: crystal growth and pharmaceutical means. SUBSTANCE: invention relates to a new method of crystallizing organic compounds, more specifically to crystallizing steroidents, namely, estrane, endrostane, pregnane, 19-norpregnane, cholestane, and their 3- and 7-substituted esters. Invention focuses on a method of crystallization of microcrystals of pharmaceutically-active substances that enables, with no recourse to mechanical operation, preparing predetermined granulometrically homogeneous class. Method consists in that, substance is dissolved in ternary mixture formed by lipophilic solvent, hydrophilic solvent, and surfactant at temperature close to boiling temperature. Then mixture is allowed to spontaneously cool to temperature at which crystallization is initiated, after which crystals are separated. EFFECT: improved quality of crystals. 25 cl, 22 dwg, 3 tbl, 37 ex
A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of up to 4.0mA direct current through two biocarbon rubber electrodes covered with at least 5mm-thick conductive electrode paste buffer, and placed over the optimized locations based on the international 10-20 system by using a combination of 10-20 EEG cap measurement and a stereotactic neuronavigation system. Stereotactic neuronavigation will be used as needed and may not be used on all participants.
Healthy societies are formed by learning and maintaining sustainable healthy eating behaviors from childhood. The aim of this study was to determine the effect of short-term sustainable nutrition education on growth and development parameters of preschool children. This study is an experimental design with pretest-posttest control group. This study was carried out in two kindergartens between February 2022 and June 2023 in Turkey. The education group received 4 months of dietary behavior training. The dietary scale and anthropometric measurements were administered at the first and last meetings. Data were analyzed with 95% confidence interval. The study was completed with 174 children. A statistically significant difference was found, especially in body weight (p < 0.05) and body weight percentile values (p < 0.05) in the posttest of the education group. A statistically significant difference (p < 0.05) was found between the groups in the eating behavior scale posttest score. Nutrition education in schools is important in promoting healthy eating habits. Nutrition education improves eating behavior positively. To maintain healthy eating behaviors, however, the continuity of education is necessary. In addition, as growth and development are physical processes, it is recognized that growth and development cannot be assessed by nutrition alone.
AIMS: To date, no studies have investigated the association between lipid species and coronary plaque changes over time, quantitatively assessed by serial imaging. We aimed to prospectively determine the association between lipid species quantified by a plasma lipidomic analysis and coronary plaque changes according to composition assessed by a quantitative serial analysis of coronary computed tomography angiography (CTA).
METHODS AND RESULTS: Patients with suspected coronary artery disease (CAD) undergoing baseline coronary CTA were prospectively enrolled by seven EU centres in the SMARTool study and submitted to clinical, molecular, and coronary CTA re-evaluation at follow-up (an inter-scan period of 6.39 ± 1.17 years). Out of 202 patients who were analysed in the SMARTool main clinical study, a lipidomic analysis was performed in 154 patients before the baseline coronary CTA, and this group was included in the present study. A quantitative CTA analysis was performed by using a separate core laboratory blinded from clinical data. In the univariable analysis, it was found that no lipid species were significantly associated with annual total and calcified plaque changes. After adjusting for clinical variables at baseline and statin use, it was found that three lipid species were significantly associated with non-calcified plaque progression. In detail, cholesteryl ester(20:3), sphingomyelin (SM)(40:3), and SM(41:1) were found to be positively related to non-calcified plaque progression (Bonferroni-adjusted P-values = 0.005, 0.016, and 0.004, respectively).
CONCLUSION: The current study showed an independent relationship between specific lipid species determined by a plasma lipidomic analysis and non-calcified coronary plaque progression assessed by a serial, quantitative coronary CTA analysis.
Transcranial random aperiodic stimulation (tRAS) delivers 1 milliampere (mA) zero-to-peak amplitude at the target electrodes and 2 mA at the return electrode. For active sham stimulation, steep-tRAS or flat-tRAS is delivered for only 15 seconds at the beginning and end of the block. This mimics the skin sensations (e.g., itching, burning, tingling) to assist with blinding the participant. Participants receive all three types of stimulation in an intermixed, balanced, and randomized order. There are twelve total blocks of approximately five minutes of stimulation with four blocks of each type of stimulation.
PURPOSE: To obtain a flavor oil which has clean and natural flavor and aroma, high stability and a long shelf life and has a volatile component and nonvolatile component containing a semisolid waxlike fraction insoluble with alcohol, and in which the nonvolatile component is a composite of compds. in a specified mol.wt. range. CONSTITUTION: A vegetable source material comprising spearmint or peppermint leaves or flowers or mixture of these is put in an extracting chamber. Supercritical CO2 is introduced into the extracting chamber by a pump to collect the mint extract. The critical temp. and critical pressure of CO2 are 31.1 deg.C and 1070psia (pound per square inch absolute), respectively. The extracted mint type flavor oil does not cause deterioration due to temp. dependance as a result of the low temp. process. Therefore, the obtd. flavor oil shows the natural flavor and aroma of the mint source material. Moreover, the oil can be mixed in various compsns. and shows characteristics with the flavor of original mint leaves, a longer life of the flavor and aroma and little deterioration by oxidation.
FIELD: medicine, stomatology. SUBSTANCE: agent for teeth cleansing comprises the following components: distilled glycerol, honey, sorbitol, finely dispersed amorphous silicon dioxide, carboxymethylcellulose sodium, sodium lauryl sulfate, aromatic composition, sodium benzoate or para- -hydroxybenzoic acid methyl ester or para-hydroxybenzoic acid propyl ester, pigmentary titanium dioxide, saccharin or sodium saccharinate, water; agent comprises polyethylene glycol (PEG)-12 or propylene glycol additionally. Agent comprises supercritical carbon dioxide concentrates of sage, walnut, field horse-tail, coneflower, rosemary. Agent promotes to treatment of mouth cavity against parodontium disease and doesn't cause irritation of mouth cavity mucous envelope. Invention can be used for mouth cavity prophylaxis. EFFECT: improved and valuable properties of agent. 3 tbl
PURPOSE:To obtain the titled complex, by bonding a substance having carcinostatic action through dextran to fibronectin. CONSTITUTION:2-200 molecules of adriamycin or daunomycin, a substance having carcinostatic action is bonded to one molecule of detran oxide, to give a complex of a substance having carcinostatic action. A reaction solution containing 1-30w/v% of the complex is reacted with fibronection in an amount to give 0.1-3w/v% final concentration. The prepared complex is purified by applying ion exchange resin of gel filtration carrier, gelatin-Sepharose, etc., to give a fibronectin complex. A ratio of fibronectin: the substance having carcinostatic action is 1:20-100. In a dose and administration method, 10-300mg of the complex is dissolved in 0.5-5ml sodium chloride injection, and used by intravenous administration, intravenous drip infusion, or drip injection.
Driver mutations are considered the cornerstone of cancer initiation. They are defined as mutations that convey a competitive fitness advantage, and hence, their mutation frequency in premalignant tissue is expected to exceed the basal mutation rate. In old terms, that translates to "the survival of the fittest" and implies that a selective process underlies the frequency of cancer driver mutations. In that sense, each tissue is its own niche that creates a molecular selective pressure that may favor the propagation of a mutation or not. At the heart of this stands one of the biggest riddles in cancer biology: the tissue-predisposition to cancer driver mutations. The frequency of cancer driver mutations among tissues is non-uniform: for instance, mutations in APC are particularly frequent in colorectal cancer, and 99% of chronic myeloid leukemia patients harbor the driver BCR-ABL1 fusion mutation, which is rarely found in solid tumors. Here, we provide a mechanistic framework that aims to explain how tissue-specific features, ranging from epigenetic underpinnings to the expression of viral transposable elements, establish a molecular basis for selecting cancer driver mutations in a tissue-specific manner.
Application of tissue engineered skin substitute with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional application of skin substitute will be applied weekly at weeks 2-11.
PURPOSE:To obtain a hair tonic, containing 1-O-(4-O-alpha-L-arabinofuranosyl-beta-D- glucopyranosyl)-1,2,3-propanetriol or a safflower extract solution containing the above- mentioned compound as an active ingredient and having preventive action on alopecia. CONSTITUTION:The objective substance, containing a novel compound expressed by the formula or a safflower extract solution containing the afore-mentioned compound and obtained by mixing a commonly used additive with a drug and preparing a pharma ceutical according to a conventional method. The hair tonic can be prepared in the form of a solution for external use, such an lotion, liniment or milky lotion, or semi solid agent for external use, such as cream, ointment, pasta, jelly or spray. The amount of the blended ingredient is 0.001-10wt.% compound expressed by the formula or 0.001-100wt.% safflower extract solution containing the above-mentioned compound. The percutaneous dose thereof is 0.0001-20mg/kg per day administered in 1-4 portions. The compound expressed by the formula is obtained by adding a water-soluble organic solvent to a hot water extract concentrate of safflower, fractionally precipitat ing the concentrate, passing the resultant supernatant through a chromatographic column and evaporation the obtained fraction to dryness under reduced pressure.
The utility model relates to a treatment device used for combined diseases of large intestine meridian, small intestine meridian two tissues, which is a device used for treating the combined diseases of large intestine meridian, small intestine meridian two tissues by introducing the traditional Chinese medicine into the human body. The device provided in the utility model is constituted by a barrel used for discharging foreign matters, a barrel used for introducing medicine, an auxiliary barrel, an ozone generator, a supersonic generator used for discharging foreign matters, supersonic wave medicine vibrating device, a supersonic generator used for introducing the medicine, and traditional Chinese medicine prescription used for treating the combined diseases of large intestine meridian, small intestine meridian two tissues. The ozone generator, the supersonic generator used for discharging foreign matters, the supersonic wave medicine vibrating device and the barrel used for introducing medicine are disposed next to the barrel used for discharging foreign matters. The ozone generator is communicated with the barrel used for discharging foreign matters, the barrel used for introducing medicine, and the auxiliary barrel by air pipes. The traditional Chinese medicine soup prepared by the supersonic wave medicine vibrating device and the purified water are disposed in the barrel used for introducing medicine. By using the device provided in the utility model, the traditional Chinese medicine molecules can not be decomposed, the dirt inside the human body can be removed, the combined diseases of large intestine meridian, small intestine meridian two tissues can be treated. The device provided in the utility model can be used for clinical diagnostic purposes.
The amber oral dose syringe should be used to withdraw the prescribed amount of sirolimus oral solution from the bottle. Empty the correct amount of sirolimus from the syringe into only a glass or plastic container holding at least two (2) ounces (1/4 cup, 60 mL) of water or orange juice. No other liquids, including grapefruit juice, should be used for dilution [see Drug Interactions (7.3), Clinical Pharmacology (12.3)]. Stir vigorously and drink at once. Refill the container with an additional volume [minimum of four (4) ounces (1/2 cup, 120 mL)] of water or orange juice, stir vigorously, and drink at once.

Sirolimus oral solution contains polysorbate 80, which is known to increase the rate of di-(2-ethylhexyl)phthalate (DEHP) extraction from polyvinyl chloride (PVC). This should be considered during the preparation and administration of sirolimus oral solution. It is important that these recommendations be followed closely.
PURPOSE: To obtain a novel polyvinyl ether alcohol which is an intermediate product for easily and efficiently yielding a polyether sulfonate which is a surfactant, such as detergents and cleaners, without the occurrence of problems, such as of poisons, environment and waste disposal.  
     CONSTITUTION: A compd. of formula I (R is a 1 to 25C alkyl, a 2 to 25C alkenyl, etc., A is a 2 to 4C 1,2-alkylene; (n) is 1 to 20). The compd. of formula I is obtd. by using 1 to 2 mol vinyloxysilane to 1 mod of a compd. of formula II and brining these compds. into reaction under atm. pressure or 10 bar pressure in the presence of a base, such as sodium hydroxide. A compd. of formula III (M is H, an alkaline metal, ammonium) is obtd. by brining the compd. of formula I into reaction with a mixture composed of the hydrogen sulfite of an alkaline metal and the sulfite of the alkaline metal. 
     COPYRIGHT: (C)1993,JPO
BACKGROUND: Allergic rhinitis (AR) is a common respiratory disease encompassing a variety of phenotypes. Patients can be sensitized to 1 or more allergens. There are indications that polysensitization is associated with more severe disease. However, the extent to which the level of sensitization is associated with clinical disease variability, underlying the distinct nature of AR from AR+ conjunctivitis or AR+ asthma, is not known.
OBJECTIVE: To evaluate phenotypical differences between monosensitized and polysensitized patients with AR and to quantify their symptomatic variability.
METHODS: A total of 565 patients with a confirmed diagnosis of AR were included in this cross-sectional study. Of those, 155 were monosensitized and 410 were polysensitized. Interactions between sensitization levels and the reporting of different symptoms of AR and co-morbidities, disease duration, and impact were assessed. Furthermore, patients were stratified into monosensitized, oligosensitized, and polysensitized to assess whether the effect of sensitization on the phenotype was ranked.
RESULTS: Polysensitized patients reported itchy eyes significantly more often (P = .001) and had a higher number of ocular (P = .005), itch-related (P = .036), and total symptoms (P = .007) than monosensitized patients. In addition, polysensitized adults and children more often reported wheeze (P = .015) and throat-clearing (P = .04), respectively. Polysensitization was associated with more burdensome AR based on a visual analog scale (P = .005). Increased sensitization level was reflected in more itchy eyes, a higher number of ocular, itch-related, and total number of symptoms, and disease burden.
CONCLUSION: With an increasing number of sensitizations, patients with AR experience an increased diversity of symptoms. Multimorbidity-related symptoms increase with sensitization rank, suggesting organ-specific thresholds.